Home Watchlists Portfolios Indices Forex Futures Market Scan Chart Settings

Here's Why Mallinckrodt Dropped 12% Today



  • Source: Yahoo Finance - - Read: 0

    Summary:

     

    Shares of Mallinckrodt (NYSE: MNK) closed down 12% on Thursday despite the company reporting positive results from the phase 3 Confirm clinical trial of its drug candidate terlipressin in patients with hepatorenal syndrome type 1 (HRS-1), a disease that stems from liver issues and often results in kidney failure and death.So what

    Mallinckrodt was light on the details from the Confirm study -- it's saving them for a medical meeting -- but the company said the clinical trial met its primary endpoint of verified HRS-1 reversal, which requires improvement in kidney function, avoidance of dialysis, and short-term survival.

    Today's decline may be because investors are worried about Mallinckrodt holding back the data, but given the lack of drugs approved to treat HRS-1 and the severity of the di ...

     

     

    Read Full News: https://finance.yahoo.com/news/apos-why-mallinckrodt-dropped-12-204800429.html


Log in to reply